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Amyloid beta selectively modulates neuronal TrkB alternative transcript
expression with implications for Alzheimer's disease
Abstract
Dysregulation in brain-derived neurotrophic factor (BDNF)/full-length TrkB (TrkB-TK+) signaling is
implicated in promoting neurodegeneration in Alzheimer's disease (AD). BDNF/TrkB-TK+ signaling can be
modulated by the presence of truncated TrkB isoforms (TrkB-TK-, TrkB-Shc). All TrkB isoforms are
encoded by different alternative transcripts. In this study, we assessed if expression of the three main
TrkB alternative transcripts, TrkB-TK+, TrkB-TK-, and TrkB-Shc are altered in AD. Using a cohort of control
and AD brains (n=29), we surveyed the hippocampus, temporal cortex, occipital cortex, and cerebellum
and found specific increases in TrkB-Shc, a neuron-specific transcript, in the AD hippocampus. No
significant changes were detected in TrkB-TK+ and TrkB-TK- transcript levels in AD in any brain region
examined. Corresponding changes in truncated TrkB protein levels were found in the hippocampus,
although a significant increase in the temporal cortex was also observed. Our findings suggested that
neuron-specific changes in TrkB may be occurring in AD; thus, we determined whether TrkB-Shc
expression could be modulated by amyloid beta 1-42 (Aβ 42). We found increased TrkB-Shc mRNA levels
in differentiated SHSY5Y neuronal cell-lines exposed to fibril-containing Aβ 42 preparations. When we
assessed the cellular impact of increased TrkB-Shc, we found co-localization between TrkB-Shc and TrkBTK+. Interestingly, TrkB-Shc overexpression selectively attenuated BDNF/TrkB-TK+-mediated signaling via
the mitogen-activated protein kinase kinase (MEK) pathway, but not the protein kinase B pathway. In AD,
MEK signaling is increased in vulnerable neurons and linked to abnormal phosphorylation of cytoskeletal
proteins. Altogether, our findings suggest that elevated TrkB-Shc expression in AD may function as a
compensatory response in neurons in AD to promote survival.
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2

Section Editor: Cellular and Molecular Neuroscience: L. Kaczmarek
Abstract
Dysregulation in brain-derived neurotrophic factor (BDNF)/full-lengthTrkB (TrkB-TK+)
signaling is implicated in promoting neurodegeneration in Alzheimer’s Disease (AD).
BDNF/TrkB-TK+ signaling can be modulated by the presence of truncated TrkB isoforms
(TrkB-TK-, TrkB-Shc). All TrkB isoforms are encoded by different alternative transcripts. In
this study, we assessed if expression of the three main TrkB alternative transcripts, TrkBTK+, TrkB-TK-, and TrkB-Shc are altered in AD. Using a cohort of control and AD brains
(n=29), we surveyed the hippocampus, temporal cortex, occipital cortex, and cerebellum and
found specific increases in TrkB-Shc, a neuron-specific transcript, in the AD hippocampus.
No significant changes were detected in TrkB-TK+ and TrkB-TK- transcript levels in AD in
any brain region examined. Corresponding changes in truncated TrkB protein levels were
found in the hippocampus although a significant increase in the temporal cortex was also
observed. Our findings suggested that neuron-specific changes in TrkB may be occurring in
AD, thus we determined whether TrkB-Shc expression could be modulated by amyloid beta
1-42 (AE). We found increased TrkB-Shc mRNA levels in differentiated SHSY5Y neuronal
cell-lines exposed to fibril-containing AEpreparations. When we assessed the cellular
impact of increased TrkB-Shc, we found co-localization between TrkB-Shc and TrkB-TK+.
Interestingly, TrkB-Shc overexpression selectively attenuated BDNF/TrkB-TK+-mediated
signaling via the MEK pathway but not the AKT pathway. In AD, MEK signaling is
increased in vulnerable neurons and linked to abnormal phosphorylation of cytoskeletal
proteins. Altogether, our findings suggest that elevated TrkB-Shc expression in AD may
function as a compensatory response in neurons in AD to promote survival.

Key Words: TrkB, BDNF, amyloid, neurotrophin, neurodegeneration, hippocampus



3

Section Editor: Cellular and Molecular Neuroscience: L. Kaczmarek
Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative diseases in humans
and is characterized by amyloid-E (AE) deposition, tau neurofibrillary tangles, and neuronal
loss. Deficits in brain-derived neurotrophic factor (BDNF) signaling have been proposed to
facilitate the progressive neurodegeneration in AD (Schindowski et al., 2008). The growth
promoting actions of BDNF are critical for survival and plasticity of a variety of neurons
throughout the brain. Moreover, BDNF has been demonstrated to be vital for neuronal
growth, differentiation, axonal guidance, behavior, cognition and memory formation; and
hippocampal neurogenesis (Knusel et al., 1991, Ghosh et al., 1994, McAllister et al., 1995,
Itami et al., 2000, Mizuno et al., 2000, Alonso et al., 2002, Lu et al., 2008, Schindowski et al.,
2008, Gao and Chen, 2009, Gao et al., 2009). The neurotrophic effects of BDNF are
mediated by the tropomyosin receptor kinase B (TrkB), a membrane-bound receptor tyrosine
kinase which can activate various cell signaling pathways linked to growth, differentiation,
and survival (Patapoutian and Reichardt, 2001, Bartkowska et al., 2010).
The TrkB gene is expressed as multiple alternative splice transcripts that give rise to
different protein isoforms (Luberg et al., 2010). Three major TrkB transcripts/isoforms are
expressed in the human brain (Stoilov et al., 2002, Luberg et al., 2010). The high affinity,
full-length (TrkB-TK+) TrkB receptor is encoded by 24 exons and is expressed primarily by
neurons. It contains a catalytic tyrosine kinase domain that is necessary for activating second
messenger signaling via the MEK, AKT, and PLCJ pathways to mediate the neurotrophic
effects of BDNF (Klein et al., 1991, Stoilov et al., 2002, Luberg et al., 2010) (Fig. 1). The Cterminal truncated TrkB receptors include TrkB-TK- and TrkB-Shc. TrkB-TK- is encoded by
16 exons and is expressed primarily by glia, although expression in neurons has also been
reported (Stoilov et al., 2002, Ohira and Hayashi, 2003, Ohira et al., 2005a, Ohira et al.,
2005b, Luberg et al., 2010). Unlike TrkB-TK+ transcripts which do not have exon 16, TrkBTK- transcripts include exon 16. Exon 16 encodes a stop codon and this leads to the
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generation of a short isoform-specific C-terminal domain that lacks the catalytic tyrosine
kinase domain (Klein et al., 1990) (Fig. 1). Thus, TrkB-TK- may inhibit neurotrophin
signaling by sequestering or trapping neurotrophins to prevent binding and signal
transduction via TrkB-TK+ homodimers (Biffo et al., 1995, Fryer et al., 1997), or act in a
manner similar to “antigen presenting” receptors by binding to BDNF and presenting it to
nearby cells expressing TrkB-TK+ (Beck et al., 1993, Frisen et al., 1993). Alternatively,
TrkB-TK- has been demonstrated in vitro to act as a dominant-negative receptor when coexpressed in the same cell type by forming inactive heterodimers with TrkB-TK+ to prevent
neurotrophin signaling (Eide et al., 1996, Ninkina et al., 1996). The other major C-terminal
truncated TrkB receptor isoform, TrkB-Shc, differs from TrkB-TK- in that it is expressed
only by neurons (Stoilov et al., 2002). It contains a sarc homology binding site (Shc) in the
juxtamembrane domain similar to TrkB-TK+, however, TrkB-Shc transcripts include exon 19
which is not present in TrkB-TK+ transcripts. Exon 19 also contains a stop codon that leads
to the translation of a unique truncated C-terminus which also lacks the tyrosine kinase
domain (Stoilov et al., 2002) (Fig. 1). Thus, TrkB-Shc may also act as a negative regulator of
TrkB-TK+ as it is able to dimerize with TrkB-TK+ but is unable to signal via tyrosine kinase
(Stoilov et al., 2002).
At present, studies examining changes in TrkB mRNA and protein expression in AD
are incomplete and conflicting changes in TrkB-TK+ and TrkB-TK- expression have been
reported. In AD brains, reductions in TrkB-TK+ protein in neurons have mostly been found
in the hippocampus and the temporal and frontal cortices (Allen et al., 1999, Ferrer et al.,
1999). Others have reported no loss of TrkB immunnoreactivity in AD parietal cortex,
however this was using an antibody to TrkB-TK- (Savaskan et al., 2000). Moreover, previous
studies of TrkB expression in the hippocampus of AD brains have only examined TrkB-TK+
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and TrkB-TK- protein expression by immunohistochemistry and western blotting (Connor et
al., 1996, Ferrer et al., 1999).
Interestingly, while the existence of TrkB-Shc has been known for some time, its role
in AD has yet to be described. Considering that TrkB-Shc has been characterized to be
expressed only in neurons (Stoilov et al., 2002), and that neurotrophin signaling is decreased
in neurons in AD, it is important to establish what role TrkB-Shc plays in AD development
and progression.
In the present study, we took a quantitative approach to specifically measure the
expression levels of each of the three major TrkB alternative splice variants (TrkB-TK+,
TrkB-TK-, and TrkB-Shc) in the hippocampus (a region heavily impacted in AD), temporal
cortex (a region also affected in AD), occipital cortex (an area affected late in AD), and
cerebellum (a region relatively spared in AD) of AD brains. Considering that TrkB-Shc is
neuronal specific, we also determined if changes in its expression could be modulated in an
amyloidogenic environment and whether increased TrkB-Shc has a functional impact on
BDNF/TrkB-TK+ signaling in a neuronal setting.
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Experimental Procedures

Brain cohorts
Two brain cohorts were used in this study. For the hippocampus and cerebellum, the brain
cohort comprised n=6 controls and n=6 AD cases (Sydney Brain Bank and New South Wales
Tissue Resource Centre, Sydney, Australia). For the temporal and occipital cortices, the brain
cohort comprised n=8 controls and n=9 AD cases (this was generously provided by Professor
Glenda Halliday). All cases were longitudinally evaluated to autopsy, and data and brain
collected for research purposes as approved by Institutional Human Ethics Committees. AD
brains were clinically and pathologically defined using NIA-Reagan criteria as described
previously (NIA, 1997, Gregory et al., 2006, Kim et al., 2010). All AD cases had Braak
neuritic stages V and VI. Demographic data for the cohorts are detailed in Table 1. Control
and AD cases were matched for age and gender where possible. The diagnostic groups did
not differ according to age, brain pH, or postmortem interval (PMI) (all p0.12). Samples
were taken from the same anatomical regions of the brain, as previously described (Kim et
al., 2010)

Cell culture and treatments
SHSY5Y cells were obtained from the American Type Culture Collection (ATCC) and
grown at 37°C in a 5% CO2 atmosphere. For continuous culture, SHSY5Y cells were
cultured in RPMI media containing 10% (v/v) FBS supplemented with glutamax (2 mM).
For experiments, SHSY5Y cells were differentiated for 9 days using all-trans retinoic acid
(ATRA:10 PM) which was added to the culture medium. During differentiation, the
differentiation media (growth media + ATRA) was refreshed every 3 days. For transfections,
differentiated SHSY5Y cells were transfected using OptiMEM medium and Lipofectamine
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2000 (Invitrogen). For treatments, serum-free RPMI media supplemented with N2 was used.
Cells were treated with BDNF for 15 min prior to harvest. For AE42 experiments, cells were
treated for 6 h and harvested. No cell-toxicity was observed in any of the treatment conditions
at the concentration employed.

RNA extraction, cDNA synthesis, and quantitative real-time PCR (qPCR)
Total RNA was extracted from tissues (20 mg) and cells using Trizol Reagent according to
the manufacturer’s instructions (Invitrogen). Concentrations of total RNA were measured
using a Nanodrop 2000c Spectrophotometer (ThermoScientific). Reverse Transcriptase-PCR
was performed according to the manufacturer’s protocol for the SuperScript III First Strand
cDNA Synthesis Kit (Invitrogen). QPCR was performed using Sso Fast Evagreen Supermix
(BioRad) on a Roche LightCycler 480 with a 96-well format (Roche). Primer pairs used for
gene expression analyses are listed in Table 2. Primers were designed to span an intron/exon
boundary to avoid amplification of possible genomic DNA. PCR cycling conditions were:
95°C for 1 min, 45 cycles of 95°C for 30 seconds, primer specific annealing temperature for
30 seconds (Table 2), and 72°C for 30 seconds. Control reactions with no template were
included which produced no signal. Melt curve analysis and agarose gel electrophoresis were
performed to confirm production of a single product. Changes in gene expression levels were
determined by normalizing mRNA levels of the gene of interest to the mRNA level of the
housekeeping gene, E-actin using the 2-''CT method (Livak and Schmittgen, 2001). E-Actin
did not vary with treatment and there was no difference in E-actin expression between control
and AD cases in any of the brain regions examined (all p>0.06) (Fig. S1A). For details on
housekeeping gene selection, please refer to the Supplemental Results.

AE42 preparation
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AE42 monomers, oligomers, and fibrils were prepared using a modified protocol from Ryan et
al. (Ryan et al., 2010). Lyophilized AE42 peptides were reconstituted in DMSO to a working
concentration of 1 mM. For experiments, 1 PM was used as the final concentration. The
volume required for each experiment was aliquoted for preparation. For monomers, aliquots
were sonicated for 10 min and briefly vortexed. For oligomer preparations, after sonication,
monomers were diluted 1:10 using PBS+0.05% SDS, vortexed for 30 seconds, and incubated
at 4C for 40 h. For fibril preparations, after sonication, monomers were diluted 1:10 using
PBS, vortexed for 30 seconds, and incubated at 37C for 40 h.

Atomic Force Microscopy (AFM)
AE42 samples (20 Pl) prepared as described above were pipetted onto the surface of freshly
cleaved 1 x 1 cm mica. Samples were incubated on the mica surface for 30 min to allow for
sufficient adsorption of the AE42 samples and then washed by exchanging the sample
solution (six times) with nanopure water. The AE42-coated mica surface was then air dried
and mounted on the AFM sample stage and static mode force measurements were performed
using an Asylum Research MFP-3D AFM (Santa Barbara, CA) as previously described
(Higgins et al., 2006). Images were captured using the Asylum Research AFM IGOR Pro
software (Wavemetrics, Lake Oswego, OR).

Immunofluorescence staining and fluorescence microscopy
SHSY5Y cells were seeded in 24-well plates containing sterile 12 × 12 mm glass coverslips
(density of: 6×104) and differentiated for 9 days as described above. Cells were transfected
with overexpression plasmids [pcDNA3.1-TrkB-Shc-myc and pcDNA3.1-TrkB-TK+-EGFP
(constructed and validated by GeneArt)] (100 ng/well) for 24 h using Lipofectamine 2000 (1
l/well) and washed twice with PBS and fixed with 3% (v/v) formaldehyde/PBS for 15 min
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at room temperature. After washing with PBS (3×5 min), cells were permeabilised with 0.1%
(v/v) Triton X-100 in PBS (5 min). After washing with PBS (3×5 min), cells were incubated
with 10% (v/v) FBS in PBS for 1 h at room temperature. Cells on the coverslips were then
incubated with primary antibody against myc (Invitrogen) 2 g diluted in 10% (v/v) FBS in
PBS plus 0.1% (w/v) saponin for 16 h at 4 °C. After washing with 10% (v/v) FBS in PBS
(3×5 min), cells were incubated with 5 g/ml of Alexa Fluor-594 conjugated mouse
secondary antibody (Molecular Probes) for 1 h at room temperature. Cells were washed with
10% (v/v) FBS in PBS (3×10 min). Coverslips were then mounted on glass slides using
ProLong® Gold antifade reagent with DAPI (Molecular probes). Images were obtained using
a Nikon ECLIPSE RE2000-E micorscope (Nikon, Japan).

Western blotting
Tissues (10mg) and cells were harvested for total protein using homogenization buffer
(human tissue) (Wong et al., 2009) or RIPA buffer (cells) supplemented with protease
inhibitors (2 mM AEBSF, 0.015 mM aprotinin, 0.038 mM leupeptin, 0.030 mM pepstatin A,
0.028 mM E-64, 0.08 mM bestatin) (Sigma) and phosphatase inhibitors (Pierce). Protein
concentrations were determined by the bicinchoninic acid method. Samples (including AE
preparations) were mixed with 5 × SDS loading buffer (containing E-mercaptoethanol),
boiled at 95ºC for 5 min, and separated on 10% or 13% SDS-PAGE gels (13% was used for
AE preparations). Proteins were transferred onto nitrocellulose membranes and blocked
using 5% (w/v) non-fat milk, 0.1% (v/v) Tween-20 in TBS (TBST) at room temperature for 1
h. For membranes containing AE samples, membranes were boiled in PBS for 5 min prior
to blocking to expose epitopes in oligomers and fibrils (Takahashi et al., 2004). Membranes
were incubated with primary antibodies: WO2 (1:500 dilution), which recognizes the AE
peptide; TrkB (1:3000) (BD Biosciences); phospho-TrkB (1:5000) (Epitomics); AKT1
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(1:5000), phospho-AKT1 (1:5000), ERK1/2 (1:20000), phospho-ERK1/2 (1:20000) (Cell
Signaling), myc (1:5000) (Invitrogen), and E-actin (1:10000) (Sigma). Membranes were
washed 3 x 10 min with TBST and incubated with mouse peroxidase-conjugated affinity
purified secondary antibody for 1 h (Dako). After further washing, bound antibodies were
incubated with enhanced chemiluminescence reagent (Millipore) and visualized by
autoradiography. Bands were quantitated by densitometry using Image J (version 1.37v)
(National Institutes of Health USA). The brightness/contrast of images was adjusted using
Adobe Photoshop CS (version 8).

Statistical analysis
All cell culture experiments were from 3 replicate cultures representative of 3-6 independent
experiments. Data are presented as mean + standard error of the mean (SEM). Outliers were
determined and removed from subsequent analyses using the Grubb’s test or if data points
were greater or less than two standard deviations from the mean (qPCR: Hippocampus:
TrkB-Shc: one control and one AD case removed; TrkB-TK-: one control and one AD case
removed; TrkB-TK+: one control removed; Temporal cortex: TrkB-Shc: one AD case
removed; TrkB-TK-: one control removed; TrkB-TK+: one control removed; Occipital
cortex: TrkB-Shc: one AD case removed; TrkB-TK-: one AD case removed; TrkB-TK+: one
AD removed; Cerebellum: TrkB-Shc: one control and two AD cases removed; TrkB-TK-:
one control removed; Protein: Hippocampus: truncated TrkB: one control removed; Temporal
cortex: full-length TrkB: one AD case removed; Occipital cortex: full-length TrkB: one AD
case removed). Statistical analyses were conducted using STATISTICA 7 (StatSoft Inc.,
2000, STATISTICA for Windows). Tests for normality were conducted. For normally
distributed data, two-tailed unpaired t-tests were conducted to assess significance in gene
expression changes. For data with non-normal distribution, the Mann Whitney U test was
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conducted. A one-way analysis of variance (ANOVA) was conducted to assess significance
in gene expression changes when incremental treatment concentrations were used. ANOVAs
were followed up with the Fischer LSD post-hoc analysis to assess the significance between
treatment groups. Pearson’s Product Moment correlations were conducted to determine if any
relationship existed between TrkB alternative transcript expression and glial fibrillary acidic
protein (GFAP) mRNA expression. A p-value less than 0.05 (two-tailed) was considered
statistically significant.
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Results

TrkB-Shc transcript levels are increased in the hippocampus of AD brains
We found highly significant increases in TrkB-Shc mRNA levels in the hippocampus of AD
brains compared to controls (t=-4.03, df=8, p=0.004) (Fig. 2A). A trend towards increased
TrkB-TK- mRNA levels was observed in the AD hippocampus compared to controls (t=2.10, df=8, p=0.07). No significant change in hippocampal TrkB-TK+ mRNA levels could be
detected between control and AD cases (t=-1.26, df=9, p=0.24).
To determine whether the increase observed in TrkB-Shc mRNA levels are related to
the location and severity of tissue pathology, we assessed whether changes in TrkB-Shc
mRNA expression are altered in the temporal cortex (a region affected after the
hippocampus) as well as the occipital cortex and cerebellum (two regions less affected in
AD). Interestingly, we found no significant change in TrkB-Shc mRNA levels in any of the
three brain regions examined between control and AD cases (all p>0.17) (Fig. 2B-D).
Moreover, no significant differences were observed in TrkB-TK- (all p>0.16) or TrkB-TK+
(all p>0.20) mRNA levels between control and AD cases.

TrkB protein expression in AD
TrkB immunoreactive bands migrating at ~140kDa (corresponding to full-length TrkB) and
~90kDa (corresponding to truncated TrkB) were detected in all control and AD samples in all
four brain regions examined (Fig. 3A). The ~90kDa band appeared large and diffuse in all
samples from all four brain regions. This is likely because the TrkB-TK- and TrkB-Shc
isoforms are similar in size and both migrate at ~90kDa. We observed significant increases in
the ~90kDa TrkB protein in the hippocampus (t=-2.67, df=9, p=0.03) and temporal cortex
(t=-3.60, df=15, p=0.003) of AD brains compared to controls (Fig. 3B and C). No significant
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difference in expression of the ~90kDa protein was observed between AD and controls in the
occipital cortex (U=16, Z=1.68, p=0.09) and cerebellum (t=-1.61, df=10, p=0.14) (Fig. 3D
and E).
Interestingly, expression of the ~140kDa band corresponding to the TrkB-TK+
protein was significantly increased in the hippocampus of AD brains compared to controls
(U=4, Z=-2.24, p=0.02) (Fig. 3B). No significant differences were observed in expression of
the ~140kDa protein in the temporal cortex, occipital cortex, and cerebellum between AD
and control brains (Fig. 3C-E) (all p>0.09).

GFAP mRNA levels in AD
Elevations in TrkB-TK- mRNA and truncated TrkB protein levels in AD have previously
been associated with increased astrocyte numbers in the diseased state (Duguid et al., 1989,
Muramori et al., 1998). To determine if the increases in TrkB-TK- mRNA (trend only) and
truncated TrkB protein levels we observed are associated with changes in astrocytes in AD,
we measured GFAP mRNA levels in the same brain regions where TrkB alternative
transcript levels were assessed. We found elevated levels of GFAP mRNA in the
hippocampus (U=5, Z=-2.08, p=0.04), temporal cortex (t=-3.47, df=15, p=0.003), and
occipital cortex (U=9, Z=-2.60, p=0.009) of AD brains compared to controls (Fig. S2A-C).
No significant change in GFAP transcript levels was observed in the AD cerebellum (t=-0.35,
df=8, p=0.73) (Fig. S2D). When we examined whether changes in TrkB-TK- mRNA and
truncated protein levels were correlated with changes in GFAP mRNA levels, we found that
TrkB-TK- mRNA levels did not correlate with changes in GFAP mRNA levels in any brain
region examined. Interestingly, we found significant positive correlations between truncated
TrkB protein expression and GFAP mRNA levels in the hippocampus (r=0.89, p=0.0003) and
temporal cortex (r=0.51, p=0.04) but no association between truncated TrkB protein and
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GFAP mRNA levels in the occipital cortex or cerebellum (all p>0.27). GFAP mRNA levels
did not correlate with TrkB-Shc, with TrkB-TK+ mRNA levels, or with full-length TrkB
protein expression in any brain region examined.

AE42
We prepared different structural forms of AE using a modified protocol from Ryan et al.
(Ryan et al., 2010). The presence of AE monomers, oligomers, and fibrils were confirmed
by western blotting (using WO2 antibody which recognizes the AE peptide) and found to be
consistent with AEpreparations previously reported by us and by others (Garzon and
Fahnestock, 2007, Kagedal et al., 2010, Ryan et al., 2010) (Fig. 4A). The monomeric AE
preparation (lane 1) contained mostly monomers (~4 kDa) but it also contained small
oligomers (12-22 kDa). We did not detect any large oligomers or fibrils. The oligomeric
AEpreparation (lane 2) contained monomers, small and large oligomers (40-70 kDa). The
fibrillar AE preparation (lane 3) contained monomers, small oligomers, some large
oligomers, and fibrils (>250 kDa).
To extend our characterization of the AE preparations utilized in this study, in
addition to western blotting, we also visualized the three different AEpreparations using
AFM (Fig. 4B). The monomer preparation contained monomers and small aggregates of
AE. These are likely to correspond to the small oligomers observed in western blot analysis
(Fig. 4A lane 1). Also similar to our findings by western blotting, we observed varying sizes
of AE oligomers and fibrils in their respective preparations by AFM. In the oligomer
preparation, we found evidence of some oligomers aggregating into fibrils (Fig. 4B and S3A).
However, it was in the fibril preparation that most fibrillar AE species were observed (Fig.
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4B and S3B), including protofibrils which can reach up to ~100 nm in length (Arimon et al.,
2005) as indicated by the black arrows in Figure S3B.

Fibrillar AE42 increases TrkB-Shc transcript levels in the differentiated SHSY5Y
neuronal cell-line
The increase in TrkB-Shc mRNA levels in the AD hippocampus but not in other brain
regions examined suggests that factors specific to severe AD pathology may be modulating
its expression. Thus, we determined whether TrkB alternative transcript expression in
neuronal cell-lines can be modulated by different species of AE. We found a modest but
significant increase in TrkB-Shc mRNA levels (t=-2.33, df=15, p=0.03) in differentiated
SHSY5Y neuronal cells treated with preparations of AE containing fibrils but not with
preparations containing monomers or oligomers(all p>0.36) (Fig. 5). No significant changes
in TrkB-TK- (all p>0.07) and TrkB-TK+ (all p>0.17) mRNA levels were observed in any of
the treatment conditions.

TrkB-Shc co-localizes with TrkB-TK+
TrkB-Shc has previously been shown to co-localize with TrkB-TK+ in non-neuronal cells
(Stoilov et al., 2002). To determine whether TrkB-Shc can co-colocalize with TrkB-TK+ in
neuronal cells, we co-overexpressed TrkB-Shc and GFP-tagged TrkB-TK+ in differentiated
SHSY5Y cells. We observed co-localisation between TrkB-TK+ and TrkB-Shc (Fig. 6). Both
TrkB-Shc and TrkB-TK+ showed cytoplasmic and plasma membrane localisation (Fig. 6A,
B, and D). Expression of both isoforms could also be observed in neurites. TrkB-TK+ was
found to localise mostly around the soma, whereas TrkB-Shc was observed to distribute into
more distal regions of neurites. Interestingly, TrkB-TK+ and to a lesser extent, TrkB-Shc,
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were found to be highly concentrated in the endoplasmic reticulum. No expression of either
isoform could be detected in the nucleus (Fig. 6A-D).

Increased TrkB-Shc expression dampens BDNF-stimulated-TrkB-TK+ mediated
second messenger signalling via the MEK pathway
We next determined whether increased TrkB-Shc protein expression impacts on
BDNF/TrkB-TK+ signaling in a neuronal setting. Differentiated SHSY5Y cells were
transiently transfected with either empty vector or myc-tagged TrkB-Shc plasmids and
treated with incremental concentrations of BDNF. In cells transfected with the empty vector
plasmid, treatment with exogenous BDNF increased TrkB, ERK1/2, and AKT
phosphorylation in a concentration dependent manner (all F>3.02, df=3, p<0.02) (Fig. 7A). In
cells transfected with TrkB-Shc-myc, BDNF treatment also increased TrkB, ERK1/2, and
AKT phosphorylation (all F>4.14, df=3, p<0.03) (Fig. 7A). No change was observed in total
protein levels in the empty vector and TrkB-Shc transfected cells with or without BDNF
treatment.
When we examined the ratio of phosphorylated to total (phosphorylated + nonphosphorylated) levels of TrkB, ERK1/2, and AKT as a measure of activity, we found that
overexpression of TrkB-Shc in differentiated SHSY5Y cells diminished the BDNFstimulated increase in pERK1:ERK1 expression ratio (comparing empty vector to TrkB-Shc
transfected at 5ng BDNF treatment: t=2.79, df=6, p=0.03; comparing empty vector to TrkBShc transfected at 15ng BDNF treatment: t=2.47, df=6, p=0.049) and abolished the BDNFstimulated increase in pERK2:ERK2 expression ratio compared to cells transfected with the
empty vector (empty vector: F=3.66, df=3, p=0.04 compared to TrkB-Shc: F=0.08, df=3,
p=0.97) (Fig. 7B). TrkB-Shc overexpression had no significant impact on BDNF-stimulated
pAKT:AKT expression ratio compared to empty vector transfected cells. Interestingly, in
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both empty vector and TrkB-Shc transfected cells, treatment of cells with 25ng of BDNF had
little effect on pAKT:AKT, pERK1:ERK1, and pERK2:ERK2 expression ratios and levels
appeared similar to the vehicle treatment condition. This finding suggests that our
experimental system was likely to have been saturated at 25ng BDNF. This is likely as
treatment with 25ng BDNF had a more potent effect at increasing the pTrkB:TrkB-TK+
expression ratio than in the empty vector (t=-3.03, df=6, p=0.02).
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Discussion
In this study, we report several novel findings: First, we found elevated levels of the neuronspecific truncated TrkB alternative transcript, TrkB-Shc in the hippocampus but not in the
temporal cortex, occipital cortex, and cerebellum of AD brains. Second, we found that
exposure of differentiated SHSY5Y neuronal cell-lines to AE preparations containing fibrils
increased TrkB-Shc transcript levels. Finally, increasing TrkB-Shc protein expression in
differentiated SHSY5Y cells attenuated BDNF-stimulated-TrkB-TK+ mediated second
messenger signaling via the MEK pathway.

TrkB-Shc and AD
To date, TrkB-Shc expression in AD brain tissues has yet to be described. Considering that
TrkB-Shc expression is neuron-specific (Stoilov et al., 2002), it is surprising that this gap in
the knowledgebase exists. Here, we show that TrkB-Shc transcripts are elevated in the AD
hippocampus, but not in the temporal cortex, occipital cortex, or cerebellum; suggesting that
increases in this TrkB alternative splice transcript is occurring in brain regions that are most
severely affected in the diseased state and that the observed increase may likely be influenced
by the neuronal cell population. In support of this, we found that TrkB-Shc mRNA levels in
differentiated neuronal cell-lines can be increased by exposure to preparations of AE
containing fibrils. Interestingly, AEpreparations that did not contain fibrillar AE species
had no significant effect on TrkB-Shc transcript levels.
At present, it is widely accepted that soluble oligomers are the more neurotoxic of the
AE species, however, evidence also indicates that the neurotoxicity of AE requires its
aggregation in the fibrillar form, particularly in the form of protofibrils (Walsh et al., 1999,
Serpell, 2000). By AFM, we were able to detect various sizes of fibrils in the fibril AE
preparations, including protofibrils which can be ~100 nm in length. Our images of the fibril
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preparations are very similar to those reported by Arimon et al. (2005). Here, the authors
found that protofibrils co-exist with larger fibrils and are able to incorporate into larger
fibrillar structures. In our preparations, we observed similar finidings. In the oligomer
preparations, while we observed evidence of some oligomers aggregating into fibrils, the
predominant form of AE were globular oligomers of various sizes. Considering that AE
fibrils are formed in the advanced stages of AD (Hoozemans et al., 2006), that the
hippocampus is the most impacted brain region, and that the CA1 subregion (the
hippocampal region assessed in this study) is the most severely impacted subregion of the
hippocampus in AD, altogether, our findings suggest that the selective increase in the TrkBShc alternative splice transcript in the AD hippocampus may be specific to severe, late stage
pathology.
In the AD hippocampus, we found a trend towards an increase in TrkB-TK- mRNA
levels but a significant elevation in truncated TrkB protein. Both TrkB-TK- and TrkB-Shc are
predicted to migrate at similar molecular weights by denaturing SDS-PAGE, thus the
increase in truncated TrkB protein is likely to reflect an increase in both TrkB-TK- and TrkBShc protein in the total hippocampal brain homogenate. While an increase in TrkB-TKmRNA levels and truncated TrkB protein are consistent with previous findings (Connor et al.,
1996, Ferrer et al., 1999), it is in contrast to the lack of change we observed in differentiated
SHSY5Y cells exposed to AE. TrkB-TK- is primarily expressed by astrocytes and previous
studies have demonstrated that TrkB-TK- signaling via Rho-GTPase is critical in regulating
astrocyte morphology (Ohira et al., 2005a). Considering that astrocytes become activated
when exposed to AE, the increase in TrkB-TK- in the AD hippocampus may be more
reflective of increases in astrocytic TrkB-TK- expression as opposed to neuronal TrkB-TKexpression. This is likely as elevations in TrkB-TK- mRNA in AD have previously been
found to be associated with reactive glia around senile plaques (Ferrer et al., 1999).
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Moreover, when we surveyed GFAP mRNA levels in the hippocampus, temporal cortex,
occipital cortex, and cerebellum, we found statistically significant elevations in all brain
regions except for the cerebellum (a region relatively spared in AD).
Interestingly, while we found no significant changes in TrkB-TK+ mRNA levels in
any of the four brain regions tested in AD compared to controls, we did find a significant
increase in full-length TrkB protein in the hippocampus. This is consistent with previous
findings which showed that both truncated and full-length TrkB immunoreactivity in the CA1
subregion of the hippocampus are elevated in AD compared to controls (Connor et al., 1996).
Moreover, both truncated and full-length TrkB immunoreactivity detected by Connor et al.
(1996) was found to localise to glial cells in association with senile plaques. Considering that
astrocytes are also able to express TrkB-TK+ mRNA and full-length TrkB protein, our
finding of elevated full-length TrkB protein in the AD hippocampus suggests that the
increase is likely to be contributed by astrocytes.
In addition to the hippocampus, we also found a significant increase in truncated TrkB
protein in the temporal cortex but not in the occipital cortex and cerebellum, consistent with
previous findings (Allen et al., 1999). The occipital cortex is affected less severely in AD and
the cerebellum is relatively spared. If we take into consideration our finding of increased fulllength TrkB protein in the AD hippocampus, and findings of elevated GFAP mRNA levels in
the hippocampus and temporal and occipital cortices, altogether, our findings may also be
reflective of the progression of AD brain pathology ie. where pathology is most severe in the
hippocampus>temporal cortex>occipital cortex>cerebellum.


Increased TrkB-Shc in AD: a negative regulator of BDNF/TrkB-TK+ signaling in AD?
The cellular response to BDNF is mediated by the full-length TrkB receptor, TrkB-TK+, and
this can be modulated depending upon the relative ratios of the full-length TrkB to truncated
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TrkB receptors (Eide et al., 1996). Changes in the relative levels of truncated TrkB receptors
have been demonstrated to have a significant impact on neuronal BDNF availability and
signaling. Co-expression of TrkB-TK- and TrkB-Shc in vitro have been found to have a
dominant negative effect on TrkB-TK+ activity (Biffo et al., 1995, Eide et al., 1996, Ninkina
et al., 1996, Stoilov et al., 2002). In accordance with these findings, we showed that TrkBShc can have a negative impact on human neuronal BDNF/TrkB-TK+ second messenger
signaling via the MEK pathway where BDNF/TrkB-TK+ mediated phosphoryation of both
ERK1 and ERK2 were reduced when exogenous TrkB-Shc was overexpressed. In contrast,
little change was obseved in BDNF-stimulated phosphorylation of TrkB and AKT when
TrkB-Shc was overexpressed. Unlike TrkB-TK+ signaling via the MEK pathway, which
requires Shc adaptor proteins to bind to phosphorylated tyrosine residues on TrkB-TK+,
signaling via AKT can also mediated via IRS1/2 (Yamada et al., 1997). Thus, the lack of
change in AKT phosphorylation upon TrkB-Shc overexpression may have resulted from
alternative pathways being utilized upon BDNF stimulation.

Increased TrkB-Shc in AD: a compensatory response to promote cell survival in AD?
While there is evidence to support the notion that increased TrkB-Shc will negatively impact
neuronal BDNF signaling (Biffo et al., 1995, Eide et al., 1996, Ninkina et al., 1996, Stoilov et
al., 2002), recent evidence suggests that TrkB-Shc may play a protective role in AD by
promoting cell survival. It was recently demonstrated that overexpression of TrkB-Shc can
modulate APP metabolism by decreasing APP intracellular domain (ICD)-mediated
transcription (AICD) (Ansaloni et al., 2011). The AICD is a positive transcriptional regulator
of apoptosis and is suggested to further accelerate neurodegeneration by contributing to the
toxic effect of A42 aggregates in vivo.
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In our current study, we found that overexpression of TrkB-Shc in differentiated
SHSY5Y cells could blunt BDNF/TrkB-TK+ stimulated MEK pathway signaling by
attenuating pERK1/2:ERK1/2 ratios (a measure of ERK1/2 activity) but with little effect on
pTrkB:TrkB-TK+ and pAKT:AKT ratios. In AD, MEK signaling and ERK1/2
phosphorylation is increased in vulnerable neurons, moreover, elevated MEK pathway
activity is implicated in the abnormal phosphorylation of tau and neurofilament proteins
(Perry et al., 1999). Considering that BDNF/TrkB-TK+ mediated neuronal survival is more
dependent upon AKT signaling than MEK signaling (Atwal et al., 2000), our finding that
elevated levels of TrkB-Shc in a neuronal setting can attenuate ERK1/2 phosphorylation
following BDNF stimulation (but have no significant effect on phosphorylated AKT and
TrkB at non-saturating levels) suggests that the increase in TrkB-Shc transcripts in the AD
hippocampus and when cells are treated with fibrillar AE, may function as a compensatory
mechanism in neurons in AD to promote survival. Further work is required to determine how
TrkB-Shc is functioning in neurons in AD and whether changes in their expression at
different stages of the disease process, in response to AE, or in response to other
amyloidogenic factors may be protective or deleterious.

Conclusions
In this study, we demonstrated a novel increase in TrkB-Shc transcript levels in the AD
hippocampus and present evidence to suggest that the increased expression of this TrkB
alternative splice transcript may be induced by exposure of neuronal cells to fibrillar AE42
species. Our finding that TrkB-Shc can preferentially dampen BDNF-stimulated TrkB-TK+
second messenger signaling via the MEK pathway but not the AKT pathway provides
compelling evidence to suggest that increases in TrkB-Shc may have a protective role in
promoting cell survival pathways but without further activating an already overactive MEK
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signaling pathway in AD. Further work aimed at identifying how splicing of the TrkB
alternative transcripts in neurons is modulated in AD would be an important step in
understanding how TrkB-Shc expression is modulated in AD.
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Figure Legends

Table 1. Cohort Demographics

Table 2. Primer Sequences

Fig. 1. TrkB gene and protein structure
In the upper panel, exons are represented by numbered rectangles, lines joining exons depict
exon splicing. Colored exons correspond to protein domains in lower panel. White exons
represent non-coding sequences. Nomenclature and gene organization derived from Luberg et
al. (Luberg et al., 2010) and Wong et al. (Wong et al., 2011).

Fig. 2. TrkB alternative transcript expression in AD
Expression of TrkB alternative transcripts in the (A) hippocampus, (B) temporal cortex, (C)
occipital cortex, and (D) cerebellum of control (white) and AD (black) brains were measured
by qPCR. **=p=0.004; #=p=0.07.

Fig. 3. TrkB protein expression in AD
Expression of truncated (90 kDa) and full-length (140 kDa) TrkB protein in the (A)
hippocampus, (B) temporal cortex, (C) occipital cortex, and (D) cerebellum of control (white)
and AD (black) brains were measured by western blotting. **=p=0.003; *=p=0.02 (140 kDa
band) and p=0.03 (90 kDa band).

Fig. 4. AE42 preparations
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(A) Lane 1 is predominantly monomers and also includes some small oligomers. Lane 2
consists of large oligomers (40-70 kDa) which are absent in lanes 1. Lane 3 consists of fibrils
(>250 kDa) which are absent in lanes 1 and 2. (B) Atomic force microscopy images of the
monomer (lane 1), oligomer (lane 2), and fibril (lane 3) preparations from panel (A). (i) The
monomer preparations contained monomers. Aggregation of monomers also can be seen. (ii)
The oligomer preparation contained monomers and oligomers of various sizes. Aggregation
of oligomers into fibrils is evident. (iii) The fibril preparation contained AE fibrils of
various sizes. Scale represents 1 Pm.

Fig. 5. Effect of different structural forms of AE42 on TrkB alternative transcript
expression in the differentiated SHSY5Y neuronal cell-line
SHSY5Y cells were differentiated for 9 days and incubated in the absence (white bars) or
presence of AE42 monomers (AEM) (grey bars), oligomers (AEO) (black bars), and fibrils
(AEF) (hatched bars) for 6 h and harvested. Expression of TrkB alternative transcripts were
then measured by qPCR. Data is expressed as mean + SEM relative to the control condition
which was set to 1. *=p=0.03. Representative of n=6 separate experiments.

Fig. 6. Localization of TrkB-TK+ and TrkB-Shc in differentiated SHSY5Y neuronal
cell-line
Differentiated SHSY5Y (A-D) cells were transfected with TrkB-TK+-EGFP or TrkB-Shcmyc for 24 h. Cells were fixed and immunoprobed with myc antibody for TrkB-Shc protein
expression (green for TrkB-TK+EGFP and red for myc tagged TrkB-Shc) and stained with
DAPI (blue). Note: no colocalization with DAPI (blue) was observed in either the green
(TrkB-TK+-EGFP) or red (myc-tagged TrkB-Shc) channels. Representative of n=3 separate
experiments.
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Fig. 7. Effect of TrkB-Shc overexpression on BDNF-stimulated TrkB-K+ second
messenger signaling in differentiated SHSY5Y neuronal cell-line
Differentiated SHSY5Y cells were transfected with either empty vector (EV; blue) or TrkBShc-myc (pink) for 24 h and treated with increasing concentrations of BDNF for 15 minutes
and harvested. Proteins were separated by SDS-PAGE and immunoprobed. (A)
Representative western blot images from n=4 independent experiments. (B) Bands were
quantitated by densitometry and presented as protein expression ratios of phosphorylated
protein to non-phosphorylated protein (pTrkB-TK+:TRkB-TK+; pAKT:AKT; pERK1:ERK1;
pERK2:ERK2) -/+ SEM. *=p=0.02 for pTrkB:TrkB-TK+ at 25ng, p=0.03 for pERK1:ERK1
at 5ng BDNF and p=0.049 for pERK1:ERK1 at 15ng BDNF. Representative of n=4 separate
experiments.

Fig. S1. E-Actin mRNA expression in AD
(A) CT values of E-actin from qPCR of the hippocampus (HP), temporal cortex (TC),
occipital cortex (OC), and cerebellum (CB) of control (white) and AD (black) brains. (B) EActin mRNA levels was normalized to the geometric mean calculated from E-actin,
cyclophillin, and porphobilinogen deaminase to show that E-actin mRNA levels is not
affected by diagnosis.

Fig. S2. GFAP mRNA expression in AD
Expression of GFAP mRNA in the (A) hippocampus (HP), (B) temporal cortex (TC), (C)
occipital cortex (OC), and (D) cerebellum (CB) of control (white) and AD (black) brains was
measured by qPCR. **=p=0.003 (temporal cortex) and p=0.009 (occipital cortex); *=p=0.04
(hippocampus).
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Fig. S3. Atomic force microscopy of AE42 species
Magnified AFM images of the (A) oligomer and (B) fibril preparations from Fig. 4. Scale
represents 0.5 Pm for (A) and 0.2 Pm for (B). Black arrows in (B) indicate protofibrils which
can reach up to ~100 nm in length.



35

Section Editor: Cellular and Molecular Neuroscience: L. Kaczmarek

Table 1. Cohort Demographics
Diagnosis
Regions
Gender
Control
hippocampus, cerebellum
Male
Control
hippocampus, cerebellum
Female
Control
hippocampus, cerebellum
Male
Control
hippocampus, cerebellum
Female
Control
hippocampus, cerebellum
Female
Control
hippocampus, cerebellum
Male
Control
occipital, temporal
Female
Control
occipital, temporal
Male
Control
occipital, temporal
Female
Control
occipital, temporal
Male
Control
occipital, temporal
Female
Control
occipital, temporal
Female
Control
occipital, temporal
Female
Control
occipital, temporal
Female
AD
hippocampus, cerebellum
Male
AD
hippocampus, cerebellum
Female
AD
hippocampus, cerebellum
Female
AD
hippocampus, cerebellum
Male
AD
hippocampus, cerebellum
Female
AD
hippocampus, cerebellum
Male
AD
occipital, temporal
Female
AD
occipital, temporal
Male
AD
occipital, temporal
Female
AD
occipital, temporal
Male
AD
occipital, temporal
Female
AD
occipital, temporal
Female
AD
occipital, temporal
Female
AD
occipital, temporal
Female
AD
occipital, temporal
Male
AD
occipital, temporal
Male
AD=Alzheimer's disease; PMI=postmortem interval
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Age (years)
82
78
69
93
85
79
61
69
73
75
77
83
91
93
83
84
83
73
83
69
65
67
68
71
75
78
78
80
83
90

PMI (h)
23.5
11
13.5
21
23
8
26
48
44
60
48
28
40
17
27
9
23
20
7
15
36
38
36
36
76
24
43
48
30
9



AGCTCAAGCCAGACACATG
TTGGCAAGACACTCCAAGTT
TGGTCTTTGAGTACATGAAGC
AATGCTGGCTTCAAGGAGACC
GAATTCTGGCCACGGCTGCTTCCAGCT

TrkB-Shc
TrkB-TKTrkB-TK+
GFAP
E-Actin

AF410901
NM_001007097
NM_001018064
NM_002055
NM_001101

Forward Sequence

Table 2. Primer Sequences
Target Gene GenBank Accession

37

TTAGTCATTAGAGCACACTGC
TCACAGCTCACAGTATATGC
TCCTGTACATGATGCTCTCTG
TTGTCCCTCTCAACCTCCAG
AAGCTTTTTCGTGGATGCCACAGGACT

Reverse Sequence
56
54
58
64
60

Primer Tm

246
256
342
254
162

Present Study
Present Study
Present Study
Present Study
Kim et al. 2010

PCR Product Size (bp) Reference
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Relative mRNA Expression
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GFAP mRNA Expression
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